Alterity Therapeutics Phase 2 Data Monitoring Committee : vi

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06,...

Related Keywords

Melbourne , Victoria , Australia , San Francisco , California , United States , David Stamler , Remy Bernarda , Hannah Howlett , European Commission , Alterity Therapeutics , Drug Administration , Nasdaq , Data Monitoring Committee , Line Data Expected , Chief Executive Officer , Multiple System Atrophy , System Atrophy , Media Contacts , Securities Act , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Rare Disease , Clinical Trials ,